Akari Therapeutics PLC (AKTX) — SEC Filings

Overview

Akari Therapeutics PLC (AKTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 16, 2026: Akari Therapeutics Plc filed an EFFECT form, indicating the effectiveness of a registration statement, on April 16, 2026. The filing relates to Act 33 and has the SEC Accession Number 9999999995-26-001192. The company's mailing and business address is 401 East Jackson Street, Suite 3300, Tampa, FL 3

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bearish, 42 neutral, 4 mixed. The dominant filing sentiment for Akari Therapeutics PLC is neutral.

Filing Type Overview

Akari Therapeutics PLC (AKTX) has filed 1 EFFECT, 1 F-6/A, 2 10-K, 32 8-K, 3 DEF 14A, 6 10-Q, 2 SC 13D/A, 1 8-K/A, 2 SC 13D with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Akari Therapeutics Plc Filing Effectiveness Notice — EFFECT · Apr 16, 2026 Risk: low
  Akari Therapeutics Plc filed an EFFECT form, indicating the effectiveness of a registration statement, on April 16, 2026. The filing relates to Act 33 and has t
• Akari Therapeutics Plc Files ADR Registration — F-6/A · Mar 31, 2026 Risk: low
  Akari Therapeutics Plc filed an F-6/A form on March 31, 2026, to register American Depository Receipt shares. The filing was accepted on the same date. Deutsche
• Akari Bets on Novel ADC Payload to Revolutionize Cancer Treatment — 10-K · Mar 30, 2026 Risk: high
  Akari Therapeutics Plc (AKTX) is an oncology company focused on developing next-generation antibody-drug conjugates (ADCs) utilizing novel, proprietary payloads
• 8-K Filing — 8-K · Dec 17, 2025
• Akari Therapeutics Files 8-K on Shareholder Votes & Financials — 8-K · Dec 16, 2025 Risk: low
  Akari Therapeutics Plc filed an 8-K on December 15, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, fo
• 8-K Filing — 8-K · Dec 8, 2025
• Akari Therapeutics Faces Delisting Concerns — 8-K · Nov 26, 2025 Risk: high
  Akari Therapeutics Plc filed an 8-K on November 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the e
• Akari Therapeutics Seeks Share Restructuring, Warrant Approval — DEF 14A · Nov 17, 2025 Risk: high
  Akari Therapeutics Plc (AKTX) is holding a General Meeting on December 15, 2025, to address several critical resolutions impacting its share structure and futur
• Akari Narrows Loss to $12M, But Intangible Impairment Hits Q3 — 10-Q · Nov 13, 2025 Risk: high
  Akari Therapeutics Plc reported a net loss of $12.0 million for the nine months ended September 30, 2025, a significant improvement from the $16.0 million net l
• Akari Therapeutics Files 8-K: Officer/Director Changes & Financials — 8-K · Oct 23, 2025 Risk: medium
  Akari Therapeutics Plc filed an 8-K on October 23, 2025, reporting events as of October 22, 2025. The filing indicates changes related to the departure of direc
• Akari Therapeutics Files 8-K: Material Agreement & Equity Update — 8-K · Oct 16, 2025 Risk: medium
  Akari Therapeutics Plc entered into a material definitive agreement on October 14, 2025. The company also reported on unregistered sales of equity securities an
• Akari Therapeutics Files 8-K — 8-K · Oct 15, 2025 Risk: low
  Akari Therapeutics Plc filed an 8-K on October 15, 2025, reporting on financial statements and exhibits. The company, formerly known as Celsus Therapeutics Plc
• Akari Therapeutics to Acquire 03 Life Sciences — 8-K · Sep 29, 2025 Risk: medium
  Akari Therapeutics Plc announced on September 26, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of 03 Life Sciences. T
• Akari Therapeutics Enters Material Definitive Agreement — 8-K · Sep 25, 2025 Risk: medium
  Akari Therapeutics Plc entered into a material definitive agreement on September 19, 2025. The company, formerly known as Celsus Therapeutics Plc and Morria Bio
• Akari Therapeutics Files 8-K: Agreements, Equity Sales, and Board Changes — 8-K · Aug 29, 2025 Risk: medium
  Akari Therapeutics Plc announced on August 28, 2025, an entry into a material definitive agreement. The company also reported on unregistered sales of equity se
• Akari Therapeutics Enters and Terminates Agreements — 8-K · Aug 21, 2025 Risk: medium
  Akari Therapeutics Plc entered into a material definitive agreement on August 15, 2025. The company also terminated a material definitive agreement on the same
• 8-K Filing — 8-K · Aug 19, 2025
• Akari Narrows Losses, Shifts Focus to ADC Platform Post-Peak Bio Merger — 10-Q · Aug 13, 2025 Risk: high
  Akari Therapeutics Plc (AKTX) reported a net loss of $5.6 million for the six months ended June 30, 2025, a significant improvement from the $13.124 million net
• Akari Therapeutics Files 8-K: Officer Changes & Shareholder Votes — 8-K · Jul 1, 2025 Risk: medium
  Akari Therapeutics Plc filed an 8-K on July 1, 2025, reporting events as of June 30, 2025. The filing indicates changes in directors or officers, the appointmen
• Akari Therapeutics Details Equity-Heavy Executive Pay in DEF 14A — DEF 14A · Jun 6, 2025 Risk: medium
  Akari Therapeutics Plc's DEF 14A filing primarily details executive compensation and equity award information for the fiscal year ending December 31, 2024, and
• Akari Therapeutics Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  Akari Therapeutics Plc filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial statemen
• Akari Therapeutics Plc Files 10-Q for Q1 2025 — 10-Q · May 14, 2025 Risk: medium
  Akari Therapeutics Plc filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals P
• Akari Therapeutics Files 8-K on Operations — 8-K · Apr 16, 2025 Risk: low
  Akari Therapeutics Plc filed an 8-K on April 16, 2025, reporting on its results of operations and financial condition, and including financial statements and ex
• Akari Therapeutics Plc Files 2024 10-K — 10-K · Apr 15, 2025 Risk: medium
  Akari Therapeutics Plc filed its 2024 10-K on April 15, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Celsus Thera
• Akari Therapeutics Announces Director Changes — 8-K · Mar 20, 2025 Risk: low
  Akari Therapeutics Plc announced on March 14, 2025, the departure of Director Dr. Jonathan Solomon and the appointment of Dr. Philip Astley-Sparke as a new dire
• Akari Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 3, 2025 Risk: medium
  Akari Therapeutics Plc announced on March 2, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equi
• Akari Therapeutics Plc Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Akari Therapeutics Plc announced a Regulation FD Disclosure on January 13, 2025. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceut
• Akari Therapeutics Board Changes Announced — 8-K · Dec 18, 2024 Risk: medium
  Akari Therapeutics Plc announced on December 12, 2024, a change in its board of directors. Dr. Clive Meanwell has been appointed as a new director, and Dr. Pete
• Akari Therapeutics Appoints New CMO, Adds Director — 8-K · Dec 16, 2024 Risk: medium
  Akari Therapeutics Plc announced on December 12, 2024, the appointment of Dr. Robert J. Spiegel as Chief Medical Officer and the election of Ms. Jennifer L. McN
• Akari Therapeutics Announces Board and Executive Changes — 8-K · Dec 12, 2024 Risk: medium
  Akari Therapeutics Plc announced on December 6, 2024, changes in its board of directors and executive compensation. Specifically, the company reported the depar
• Patel Amends Akari Therapeutics Stake Filing — SC 13D/A · Dec 6, 2024 Risk: medium
  Samir Rashmikant Patel filed an amendment (No. 1) to Schedule 13D on November 14, 2024, regarding Akari Therapeutics Plc. This filing indicates a change in the
• Akari Therapeutics Plc Files Q3 2024 10-Q — 10-Q · Nov 19, 2024 Risk: medium
  Akari Therapeutics Plc filed a 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financial da
• Akari Therapeutics Plc Files 8-K with Multiple Material Events — 8-K · Nov 14, 2024 Risk: high
  Akari Therapeutics Plc announced on November 13, 2024, that it has entered into a material definitive agreement related to the completion of an acquisition or d
• Akari Therapeutics Files 8-K on Shareholder Votes and Filings — 8-K · Nov 8, 2024 Risk: low
  Akari Therapeutics Plc filed an 8-K on November 7, 2024, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial
• Akari Therapeutics Faces Nasdaq Delisting Warning — 8-K · Oct 4, 2024 Risk: medium
  Akari Therapeutics Plc announced on October 1, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules due to
• Akari Therapeutics Appoints New CMO, Elects Director — 8-K · Sep 18, 2024 Risk: medium
  Akari Therapeutics Plc announced on September 13, 2024, the appointment of Dr. Jonathan Solomon as Chief Medical Officer and the election of Ms. Sarah O'Connor
• Akari Therapeutics Files 8-K on Financing and Warrants — 8-K · Sep 6, 2024 Risk: medium
  Akari Therapeutics Plc filed an 8-K on September 6, 2024, reporting on other events and financial statements. The filing references various financing activities
• Akari Therapeutics Plc Files 8-K/A for Director and Officer Changes — 8-K/A · Aug 23, 2024 Risk: medium
  Akari Therapeutics Plc filed an 8-K/A on April 25, 2024, to report changes in its board of directors and compensatory arrangements. Specifically, the filing det
• Akari Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 19, 2024 Risk: medium
  Akari Therapeutics Plc filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position and business operations, including det
• Akari Therapeutics Plc Files 8-K on Shareholder Vote — 8-K · Jul 1, 2024 Risk: low
  Akari Therapeutics Plc filed an 8-K on July 1, 2024, reporting on a matter submitted to a vote of security holders as of June 28, 2024. The filing details the c
• RPC Pharma Ltd Amends Akari Therapeutics Stake — SC 13D/A · Jun 20, 2024 Risk: medium
  On June 20, 2024, RPC Pharma Ltd, acting as trustee for the Sonic Healthcare Holding Co, filed an amendment (Amendment No. 8) to its Schedule 13D for Akari Ther
• Theofilos Charles Steve reports 1.9% stake in Akari Therapeutics — SC 13D · Jun 18, 2024 Risk: medium
  On May 31, 2024, Theofilos Charles Steve filed a Schedule 13D for Akari Therapeutics Plc, reporting beneficial ownership of 1,000,000 ordinary shares, represent
• Patel Discloses 1.9% Stake in Akari Therapeutics — SC 13D · Jun 7, 2024 Risk: medium
  On May 31, 2024, Samir Rashmikant Patel filed a Schedule 13D for Akari Therapeutics Plc, reporting beneficial ownership of 1,000,000 ordinary shares, representi
• Akari Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jun 5, 2024 Risk: medium
  Akari Therapeutics Plc filed an 8-K on June 5, 2024, reporting events as of May 31, 2024. The filing primarily concerns the departure of directors or certain of
• Akari Therapeutics Enters Definitive Agreement, Discloses Equity Sales — 8-K · Jun 4, 2024 Risk: medium
  Akari Therapeutics Plc announced on May 29, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity
• Akari Therapeutics Plc Files Definitive Proxy Statement — DEF 14A · Jun 3, 2024 Risk: low
  Akari Therapeutics Plc filed a definitive proxy statement (DEF 14A) on June 3, 2024, for its annual general meeting. The filing details the company's governance
• Akari Therapeutics Files 8-K on Financials — 8-K · May 16, 2024 Risk: low
  Akari Therapeutics Plc filed an 8-K on May 16, 2024, reporting on its results of operations and financial condition. The filing includes financial statements an
• Akari Therapeutics Plc Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: medium
  Akari Therapeutics Plc (AKTX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Akari Therapeutics Plc filed a 10-Q report for the period ending Mar
• Akari Therapeutics Announces CMO Departure, Appoints Interim — 8-K · May 7, 2024 Risk: medium
  Akari Therapeutics Plc announced on May 1, 2024, the departure of its Chief Medical Officer, Dr. Robert James, and the appointment of Dr. Jonathan Solomon as in
• Akari Therapeutics Director Departs, Files 8-K — 8-K · May 1, 2024 Risk: low
  Akari Therapeutics Plc announced on April 25, 2024, the departure of Dr. Robert L. Finberg from its Board of Directors. The company also reported on compensator

Frequently Asked Questions